Clinical trials: Nerve Condition
Neurofibromatosis Type 1, Plexiform Neurofibromas
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
This is a phase II, multicenter, randomised, parallel, double-blind, placebo-controlled study assessing the efficacy and safety of the MEKi selumetinib compared with placebo in Chinese paediatric participants with post-operative…
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative
- Trial name
- PROTECT (NCT05825365)
- Testing
- Selumetinib
- Sponsor
- AstraZeneca
Melanoma
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
The purpose of this study is to determine the survival rate after 1 year of treatment with ipilimumab plus dacarbazine in patients with previously untreated Stage III (unresectable) or Stage IV melanoma.
- Trial name
- NCT01681212
- Testing
- Ipilimumab, Dacarbazine
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or…
- Trial name
- NCT05987332
- Testing
- IDE196, Crizotinib, Pembrolizumab
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 420 people
- Sponsor
- IDEAYA Biosciences
Melanoma
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant advanced/metastatic melanoma.
- Trial name
- NCT03878719
- Testing
- binimetinib, encorafenib
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Pfizer
Melanoma
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment.
- Trial name
- CALMext (NCT01636882)
- Testing
- CVA21
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Viralytics
Painful Diabetic Neuropathies
Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
- Trial name
- NCT01475786
- Testing
- Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202)
- Where
- 17 sites in United States, South Korea
- Volunteers
- 104 people
- Sponsor
- Helixmith Co., Ltd.
Lumbosacral Radicular Pain, Sciatic Radiculopathy
Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy
The purpose of this study is to evaluate the safety and tolerability of C-1101 administered as a single dose, transforaminal epidural injection compared to sterile saline
- Conditions
- Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain, Sciatica
- Trial name
- NCT07264270
- Testing
- C-1101
- Where
- 6 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Consano Bio
Pain, Postoperative, Bunion
Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
This two-part study will be conducted in male and female patients 18 to 65 years of age undergoing bunionectomy. Part I - three-step, single ascending dose study design in which two drug loads (low drug load of funapide and high…
- Trial name
- NCT04826328
- Testing
- FX301, Normal Saline
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Progressive Supranuclear Palsy
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.
- Trial name
- NCT04993768
- Testing
- TPN-101, 100 mg/day, TPN-101, 200 mg/day, TPN-101, 400 mg/day
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- Transposon Therapeutics, Inc.
Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV)
Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients
This is an open label, single arm, prospective, and pilot study. Eligible patients will be enrolled after acquiring the signed informed consent and then will receive the treatment of re-RT combined with FUS (FUS + re-RT) on an…
- Conditions
- Recurrent Glioblastoma, High-Grade Glioma (WHO III-IV), Brain Tumor Recurrent, Brain Tumor Adult
- Trial name
- NCT04988750
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 7 people
- Sponsor
- NaviFUS Corporation
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
- Trial name
- Tauros (NCT01049399)
- Testing
- tideglusib
- Where
- 24 sites in United States, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Noscira SA
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C.
- Conditions
- Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
- Trial name
- NCT03888716
- Testing
- KL1333
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Abliva AB
Advanced Solid Tumor, Melanoma
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of BAT4706 Injection in Patients With Advanced Solid Tumors.
- Trial name
- NCT05148325
- Testing
- BAT4706
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Bio-Thera Solutions
Overactive Bladder, Urge Incontinence
eCoin for OAB Feasibility Follow-on Study
This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American…
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03655054
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 7 sites in United States, New Zealand
- Volunteers
- 23 people
- Sponsor
- Valencia Technologies Corporation
Melanoma
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who…
- Trial name
- NCT04835805
- Testing
- Belvarafenib, Cobimetinib, Nivolumab
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
- Conditions
- Ovarian Neoplasms, Non-Small-Cell Lung Carcinoma, Melanoma, Other Solid Tumors
- Trial name
- NCT02711345
- Testing
- LTT462
- Where
- 7 sites in United States, Germany and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.